A new report released by GlobalData projects a modest increase in the global schizophrenia treatment market value
A new report released by GlobalData, PharmaPoint: Schizophrenia – Global Drug Forecast and Market Analysis to 2022, projects a modest increase in the global schizophrenia treatment market value. Value is expected to climb from $6.3 billion in 2012 to $7.9 billion by 2022, with a Compound Annual Growth Rate of 2.4%.
Out of the seven major markets (US, France, Germany, Italy, Spain, the UK, and Japan), the dominant player in the schizophrenia space in 2012 was the US, with sales of $5.2 billion and a global share of 83%, the report shows. The US is expected to maintain its position by 2022, with sales reaching $6.1 billion (a representation of 1.6% Compound Annual Growth Rate).
The report suggests that the rising awareness of mental health is partially responsible for the market expansion, along with increased utilization of long-acting injectable antipsychotics.
While four new drugs are due to enter into the market during the forecast period (Otsuka’s brexpiprazole, Roche/Chugai’s bitopertin, EnVivo’s EVP-6124, Alkermes’ aripiprazole lauroxil and Johnson & Johnson’s (J&J) Invega Sustenna (Three-Month)), Kyle Nicholson, PharmD, GlobalData's Analyst covering Neurology, says: “These latter two drugs will introduce new LAI treatments and expand the global market options by 33%. The three-month version of J&J’s Invega Sustenna in particular will provide patients with a reduced dosing burden."
Nicholson also notes, “As novel products in an emerging part of the schizophrenia drug market, these agents could be met with significant sales, due to their higher costs of therapy and a growing popularity of LAIs in this space.”
However, high costs resulting in a push towards generics, and the sheer level of unmet need in schzophrenia and other mental health disorders, present significant barriers to the market.
*PharmaPoint: Schizophrenia – Global Drug Forecast and Market Analysis to 2022
Read the full release here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.